Skip to main content

Advertisement

SpringerLink
Log in

Preparation, Characterization and Cytotoxic Effects of Pegylated Nanoliposomal Containing Carboplatin on Ovarian Cancer Cell Lines

  • Original Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Carboplatin is a chemotherapeutic agent used against various malignancies such as ovarian carcinoma. The aim of this study is to improve the therapeutic efficacy of carboplatin using pegylated liposomal nanocarriers. Nanoparticles were synthesized using thin film hydration technique and characterized for shape morphology, particle size, zeta potential and drug-release properties. In the next step, A2780S and A2780CP ovarian cancer cell lines were used to determine the efficacy of nanodrug by MTT assay. The particle size and zeta potential of nanodrug were measured 244.3 ± 19.6 nm and −22.9 ± 1.7 mV, respectively. High encapsulation capacity (78.6 ± 3.7 %) confirmed the efficiency of technique. The cytotoxicity results also showed that nanodrug compared to free drug improve the efficacy of carboplatin against both A2780S (P < 0.01) and A2780CP (P < 0.05) cell lines. In conclusion, the findings of our study suggested pegylated liposomal nanocarriers are proper for carboplatin delivery to ovarian cancer cell lines A2780S and A2780CP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res. 2012;31:14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Arab M, Khayamzadeh M, Tehranian A, Tabatabaeefar M, Hosseini M, Anbiaee R, et al. Incidence rate of ovarian cancer in Iran in comparison with developed countries. Indian J Cancer. 2010;47:322–7.

    Article  CAS  PubMed  Google Scholar 

  3. Lambert LA. Looking up: recent advances in understanding and treating peritoneal carcinomatosis. CA Cancer J Clin. 2015;65:284–98.

    Article  PubMed  Google Scholar 

  4. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12:237–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Liu E, Zhou Y, Liu Z, Li J, Zhang D, Chen J, et al. Cisplatin loaded hyaluronic acid modified TiO2 nanoparticles for neoadjuvant chemotherapy of ovarian cancer. J Nanomater. 2015;16:275–82.

    Google Scholar 

  6. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185–98.

    Article  CAS  PubMed  Google Scholar 

  7. Kopel P, Wawrzak D, Moulick A, Milosavljevic V, Kizek R. Nanotransporters for anticancer drugs, modifications, target molecules. J Metallomics Nanotechnol. 2015;2:32–8.

    Google Scholar 

  8. Della Pepa C, Tonini G, Pisano C, Di Napoli M, Cecere SC, Tambaro R, et al. Ovarian cancer standard of care: are there real alternatives? Chin J Cancer. 2015;34:17–27.

    Article  CAS  PubMed  Google Scholar 

  9. Schmitt A, Gladieff L, Laffont CM, Evrard A, Boyer JC, Lansiaux A, et al. Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. J Clin Oncol. 2010;28:4568–74.

    Article  CAS  PubMed  Google Scholar 

  10. Shahbazian S, Akbarzadeh A, Torabi S, Omidi M. Anti-cancer activity of pegylated liposomal trans-anethole on breast cancer cell lines MCF-7 and T47D. Biotechnol Lett. 2015;37:1355–9.

    Article  CAS  PubMed  Google Scholar 

  11. Zhang J, Huang C, Huang H. Antitumor and antimetastasis effects of carboplatin liposomes with polyethylene glycol-2000 on SGC-7901 gastric cell-bearing nude mice. Oncol Lett. 2014;8:2209–14.

    PubMed  PubMed Central  Google Scholar 

  12. Chaudhury A, Das S, Bunte RM, Chiu GN. Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft. Int J Nanomed. 2012;7:739–51.

    CAS  Google Scholar 

  13. Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems-a review (part 2). Trop J Pharm Res. 2013;12:265–73.

    Google Scholar 

  14. Cho Y, Shi R, Borgens RB, Ivanisevic A. Functionalized mesoporous silica nanoparticle-based drug delivery system to rescue acrolein-mediated cell death. Nanomedicine (Lond). 2008;3:507–19.

    Article  CAS  Google Scholar 

  15. Otsuka H, Nagasaki Y, Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev. 2003;55:403–19.

    Article  CAS  PubMed  Google Scholar 

  16. Jamali B, Nakhjavani M, Hosseinzadeh L, Amidi S, Nikounezhad N, Shirazi FH. Intracellular GSH alterations and its relationship to level of resistance following exposure to cisplatin in cancer cells. Iran J Pharm Res. 2015;14:513–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Nejdl L, Kudr J, Blazkova I, Chudobova D, Skalickova S, Ruttkay-Nedecky B, et al. Mechanisms of uptake and interaction of platinum based drugs in eukaryotic cells. Platinum metals in the environment. Berlin: Springer; 2015. p. 401–15.

    Google Scholar 

Download references

Acknowledgments

This study was the M.Sc. thesis of the first author that was approved by institute review board of Islamic Azad University, Shahreza Branch, Shahreza, Iran with code number of (19710603932016) and supported by Department of Pilot Nanobiotechnology, Pasteur Institute of Iran, Tehran, Iran which hereby thanks to all colleagues.

Author information

Authors and Affiliations

  1. Department of Toxicology, Faculty of Pharmacy, Islamic Azad University, Shahreza Branch, Shahreza, Iran

    Meysam Ebrahimifar & Hassan Madadizadeh

  2. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Hamadan University of Medical Sciences, P.O. Box 8678-3-65178, Hamadan, Iran

    Amir Nili-Ahmadabadi

  3. Department of Pilot Nanobiotechnology, Pasteur Institute of Iran, Tehran, Iran

    Azim Akbarzadeh

  4. Department of Microbiology, Parasitology and Immunology, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

    Hasan Ebrahimi Shahemabadi

  5. Department of Chemical Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran

    Majid Hasanzadegan

  6. Department of Biochemistry, Tehran University of Medical Science, Tehran, Iran

    Hemen Moradi-Sardareh

  7. Department of Genetics, School of Advanced Sciences in Medicine, Islamic Azad University, Tehran, Iran

    Jalal Rezaee-diyan

Authors
  1. Meysam Ebrahimifar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amir Nili-Ahmadabadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Azim Akbarzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hasan Ebrahimi Shahemabadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Majid Hasanzadegan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hemen Moradi-Sardareh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hassan Madadizadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jalal Rezaee-diyan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amir Nili-Ahmadabadi.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ebrahimifar, M., Nili-Ahmadabadi, A., Akbarzadeh, A. et al. Preparation, Characterization and Cytotoxic Effects of Pegylated Nanoliposomal Containing Carboplatin on Ovarian Cancer Cell Lines. Ind J Clin Biochem 32, 230–234 (2017). https://doi.org/10.1007/s12291-016-0596-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-016-0596-3

Keywords

Search

Navigation